ReviewAbdominal radiology (New York)2026
PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Impact of structured reporting on interpretability of PSMA PET/CT in prostate cancer staging-towards standardised clinical implementation.European radiology experimental · 2026Article
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PSMA-RADS version 1, introduced by Rowe et al. in 2017, provides a framework for classifying PSMA-targeted PET scans and individual findings based on their likelihood of representing prostate cancer. The system was optimized for findings outside the prostate and was structured as a five-point scale (Rowe et al., Eur Urol 73:485-487, 2018. https://doi.org/10.1016/j.eururo.2017.10.027 . In 2022, an updated PSMA-RADS version was proposed to refine category definitions, address limitations of the initial version, and enhance its role in guiding clinical decisions. The framework includes both lesion-level and patient-level classifications, offering confidence and probability scores in support of clinical decision-making (Leung et al., EJNMMI Res. https://doi.org/10.1186/S13550-022-00948-1 ). This article aims to explore the changes introduced in the updated scale and evaluate their impact on clinical management. It is intended to inform abdominal and general radiologists about recent developments in PSMA-targeted imaging to support multidisciplinary collaboration and patient care.
Indexed as
Identifiers
40514459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.